Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02360592
Other study ID # Endeavor study, a pilot study
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date June 2013
Est. completion date April 2017

Study information

Verified date October 2017
Source Tongji Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a multi-center, randomized, prospective, open-label Phase IV Clinical trial to evaluate efficacy and safety of interferon alfa-2b therapy combinated with interleukin 2 and hepatitis B therapeutic vaccine versus interferon alfa-2b alone in chronic hepatitis B patients with entecavir achieving HBeAg seroclearance. Patients were randomized to one of 3 groups to receive different antiviral treatment.


Description:

Patients who have been pretreated with entecavir for at least one year, with HBV (Hepatitis B Virus) DNA less than 1000 copies/ml and HBeAg seroclearance were randomized to one of 3 groups, to receive Entecavir 0.5 mg po daily for 72 weeks, or Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks, or Interferon alfa-2b 600wIU qod iH for 48 weeks plus Entecavir 0.5mg qd po for 8 weeks plus interleukin 2 25 wIU qod iH for 12 weeks plus Hepatitis B Vaccine 60ug qm im for 48 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 94
Est. completion date April 2017
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Male and female patients from 18 to 65 years of age;

2. Undergoing treatment with entecavir for at least 1 year ;

3. HBsAg(+), HBeAg(+), HBV DNA= 100000 copies/ml,ALT=2 ULN and =10 ULN before receiving entecavir treatment;

4. HBV DNA =1000 copies/mL;

5. HBeAg (-);

6. HBsAg (+);

7. Negative urine or serum pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of test drug;

8. Liver biopsy confirmed without cirrhosis (optional);

9. Agree to participate in the study and sign the patient informed consent.

Exclusion Criteria:

1. Patients who had NAs resistance;

2. Other antiviral, anti-neoplastic or immunomodulatory treatment (including supra physiologic doses of steroids and radiation) 6 months prior to the first dose of randomized treatment (except for 7 days of acyclovir for herpetic lesions more than 1 month prior to first administration of randomized treatment). Patients who are expected to need systemic antiviral therapy other than that provided by the study at any time during their participation are also excluded;

3. Women with ongoing pregnancy or breast-feeding;

4. Co-infection with active hepatitis A, hepatitis C, hepatitis D(Those hospitals which have the ability to do the test will do) and/or human immunodeficiency virus (HIV);

5. ALT >10 ULN;

6. Evidence of decompensated liver disease (Child-Pugh score > 5 ). Child-Pugh > 5 means, if one of the following 6 conditions are met, the patient has to be excluded: a. Serum albumin < 3.5 g/L; b. Prothrombin time > 3 seconds prolonged; c. Serum bilirubin > 34 ยต mol/L; d. History of encephalopathy; e. History of variceal bleeding; f. Ascites;

7. History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures, thalassemia);

8. Signs or symptoms of hepatocellular carcinoma, patients with a value of alpha-fetoprotein > 100 ng/mL are excluded, unless stability (less than 10% increase) has been documented over at least the previous 3 months. Patients with values < 20 ng/mL but > 100 ng/mL may be enrolled, if hepatic neoplasia has been excluded by liver imaging;

9. Neutrophil count < 1500 cells/mm3 or platelet count <90,000 cells/mm3 at screening;

10. Hemoglobin < 11.5 g/dL for females and <12.5 g/dL for men;

11. Serum creatinine level > 1.5 ULN in screening period.

12. Phosphorus < 0.65 mmol/L;

13. ANA > 1:100;

14. History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at herapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease;

15. History of a severe seizure disorder or current anticonvulsant use;

16. History of immunologically mediated disease, (e.g., inflammatory bowel disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, rheumatoid arthritis etc.);

17. History of chronic pulmonary disease associated with functional limitation;

18. Diseases that IFN and Nucleotides or nucleosides are not suitable.

Study Design


Intervention

Drug:
Entecavir
In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.
Interferon alfa-2b
In arm 2 and 3, interferon alfa-2b is used for 48 weeks
Interleukin 2
In arm 3, Interleukin 2 is used for 12 weeks
Hepatitis B Vaccine
In arm 3, Hepatitis B Vaccine is used for 48 weeks

Locations

Country Name City State
China BeiJing YouAn Hospital, Capital Medical University Beijing Beijing
China First Hospital, Beijing University Beijing Beijing
China People'S Hospital Under Beijing University Beijing Beijing
China Departmen of infectious disease, Xiangya Hospital, Central-south Universit Changsha Hunan
China The First Affiliated Hospital of Fujian Medical University Fuzhou Fujian
China Department of infectious disease, Nanfang Hospital of Southern Medical University Guangzhou Guangdong
China The First Affiliated Hospital of College of Medicine, Zhejiang University Hangzhou Zhejiang
China Anhui Provincial Hospital Hefei Anhui
China Shanghai Ruijin Hospital, Jiao Tong University School of Medicine Shanghai Shanghai
China ShengJing Hospital of China Medical University Shenyang Liaoning
China The first affiliated hospital of Wenzhou medical universtiy Wenzhou Zhejiang
China Tongji Hospital Wuhan Hubei

Sponsors (3)

Lead Sponsor Collaborator
Tongji Hospital Beijing Kawin Technology Share-Holding Co., Ltd., Fujian Cosunter Pharmaceutical Co. Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Percentage of HBeAg seroconversion at week 48 Percentage of HBeAg seroconversion are measured at week 48 week 48
Other Percentage of HBV DNA normalization Percentage of HBV DNA normalization is measured. week 48
Other Percentage of sustained virology response at week 72 Sustained virology response is measure at follow up week 24 week 72
Other Percentage of ALT normalization at week 48 Percentage of ALT normalization at week 48 is measured. week 48
Primary Percentage of HBsAg loss at week 48 Change from baseline in Percentage of HBsAg loss at week 48 week 48
Secondary decline from baseline in HBsAg quantification at week 48 HBsAg quantification are measured. week 48
Secondary Change from baseline in HBsAg seroconversion at week 48 HBsAg seroconversion from baseline is measured. week 48
See also
  Status Clinical Trial Phase
Completed NCT03272009 - Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects Phase 1
Recruiting NCT01456312 - HBsAg Related Response Guided Therapy Phase 4
Terminated NCT01886300 - An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam N/A
Completed NCT01023230 - A Study to Assess DV-601 in Subjects With Chronic Hepatitis B Phase 1
Completed NCT00962975 - A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies Phase 1
Completed NCT00536263 - PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327) Phase 3
Terminated NCT00460850 - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B. Phase 4
Completed NCT03681132 - The Norwegian Nucleoside Analogue Stop Study Phase 4
Active, not recruiting NCT05473806 - Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes Phase 4
Withdrawn NCT01179594 - A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B. Phase 4
Recruiting NCT05057065 - A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB
Completed NCT04439539 - A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection Phase 2
Withdrawn NCT03125213 - A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects Phase 2
Active, not recruiting NCT04782375 - Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B Phase 4
Withdrawn NCT05550519 - A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment Early Phase 1
Completed NCT02693652 - A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine Phase 1/Phase 2
Enrolling by invitation NCT04160897 - Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
Active, not recruiting NCT02588937 - Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Phase 4
Completed NCT02612506 - Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers Phase 1
Recruiting NCT02327416 - A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study) Phase 3